CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±èÀº°æ
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ¸¸¼ºÆó¼â¼ºÆóÁúȯ, Æó°áÇÙ, °£Áú¼ºÆóÁúȯ, Æó¾Ï
  • Á÷ À§: ºÎ±³¼ö
  • ¸Þ ÀÏ:
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
38 (±¹³»)SCI Predictors of Pulmonary Function Response to Treatment with Salmeterol/fluticasone in Patients with Chronic Obstructive Pulmonary Disease
37 (±¹¿Ü)SCI Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxaemia
36 (±¹³»)SCOPUS A Rare Case of Fat-Forming Variant of Solitary Fibrous Tumor Presenting as a Pleural Mass
35 (±¹³»)SCOPUS ±¹³» ¹Î°£º´¿ø¿¡¼­ Ä¡·áÇÑ ´ÙÁ¦³»¼º°áÇ٠ȯÀÚÀÇ Ä¡·á °á°ú ¹× ¿¹ÈÄ ÀÎÀÚ
34 (±¹¿Ü)SCI Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema
33 (±¹³»)±âŸ small cell lung cancer at subcarina presenting as a metastatic brain tumor
32 (±¹¿Ü)SCI Three phenotypes of obstructive lung disease in the elderly
31 (±¹¿Ü)SCIE Association of endothelial nitric oxide synthase polymorphisms and haplotypes with ischemic stroke in Korean individuals with or without diabetes mellitus
30 (±¹¿Ü)SCI Treatment Outcomes and Survival Based on Drug Resistance Patterns in Multidrug-resistant Tuberculosis
29 (±¹¿Ü)SCI p16Ink4a Suppression of Lung Adenocarcinoma by Bmi-1 in the Presence of p38 Activation
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729